PDL BioPharma is increasingly focused on building Noden Pharma (of which it currently owns 98%) into a lucrative specialty pharmaceutical platform. Currently Noden sells Tekturna, a hypertension drug acquired from Novartis, which had sales of $156m in 2015. It is actively searching for additional products to sell through Noden and is prioritizing these investments over additional royalty and note deals (although current investments in these areas should continue to provide cash flow). We valu
28 Mar 2017
Building the Noden platform
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Building the Noden platform
- Published:
28 Mar 2017 -
Author:
Maxim Jacobs -
Pages:
13
PDL BioPharma is increasingly focused on building Noden Pharma (of which it currently owns 98%) into a lucrative specialty pharmaceutical platform. Currently Noden sells Tekturna, a hypertension drug acquired from Novartis, which had sales of $156m in 2015. It is actively searching for additional products to sell through Noden and is prioritizing these investments over additional royalty and note deals (although current investments in these areas should continue to provide cash flow). We valu